Medical Laboratories (U.S.) — NAICS 621511

An investor's primer on the independent labs that analyze blood, tissue, and DNA — the diagnostic backbone of U.S. health care.

1. Overview

A medical laboratory takes a physical specimen — blood, urine, a tissue biopsy, a cheek swab — and turns it into a result a doctor can act on: a cholesterol number, a strep culture, a cancer's genetic profile. This is the diagnostic layer of medicine. The industry likes to cite that laboratory testing informs roughly 70% of medical decisions while accounting for a small share of total health spending; the exact figure is debated, but the point stands — labs are cheap, high-volume, and decision-critical.[1]

NAICS (North American Industry Classification System) code 621511 covers the independent medical labs — standalone companies that run analytic and diagnostic tests, including body-fluid analysis, on referral from doctors, hospitals, and patients.[2] It deliberately excludes the two places where most U.S. lab testing actually happens: inside hospitals and inside doctors' offices (more on that undercount in Section 3). So the federal numbers describe a real, sizable industry — but one slice of a larger testing economy.

Why it matters. Demand is defensive and demographically tailwinded — an aging, chronically ill population needs more tests every year — the work is recurring, and the economics have high operating leverage: once a lab is built, each additional specimen is highly profitable. The catch is that a lab does not set most of its own prices; government and insurers do.

Two ways in. The public market offers two national scale operators (Quest Diagnostics and Labcorp) plus a cohort of fast-growing specialty/genomic testers (Exact Sciences, Natera, Guardant Health, and others). Private capital shows up as private-equity roll-ups of regional labs, physician-led pathology groups, hospital-system outreach labs being sold to the majors, and venture funding of diagnostic startups. Some of the most respected labs — Mayo Clinic Laboratories, ARUP, Cleveland Clinic Laboratories — are academic or health-system reference operations and not investable at all. The core investment case is durable testing demand plus scale benefits from automation, logistics, payer contracting, and centralized processing; the central risk is that payers, not labs, largely set reimbursement.

2. What it is and how it's structured

The operating chain. A physician orders a test → a specimen is collected and transported → the lab processes and interprets it → results are returned electronically or in a report → the lab bills a health plan, government program, institution, or patient.[9]

Scope (what 621511 includes): establishments primarily doing analytic or diagnostic testing on specimens — blood-analysis labs, anatomic-pathology labs, bacteriological/microbiology labs, molecular and genetic testing labs, and general medical testing labs.[2] Major service categories:

• Routine clinical testing — chemistry, hematology, microbiology, urinalysis, toxicology.
• Anatomic pathology — tissue and cytology examination.
• Molecular and genetic testing — sequencing, oncology assays, reproductive/prenatal testing, transplant monitoring.
• Reference testing — specialized tests referred in by hospitals, physician offices, or smaller labs.

What it excludes (and the adjacent codes):

• Diagnostic Imaging Centers — NAICS 621512. X-ray, MRI (magnetic resonance imaging), CT (computed tomography), ultrasound. These make images; they don't analyze specimens.[2]
• Blood and organ banks — NAICS 621991. Collection and storage of blood/organs.[2]
• Hospital labs — inside NAICS 622 (Hospitals). A hospital's own lab is counted as part of the hospital, not here.
• Physician-office labs — inside NAICS 6211 (Offices of Physicians). The quick tests a doctor's practice runs in-house.
• Dental, optical, and orthopedic labs — classified as manufacturing (NAICS 339116, 339115, 339113).
• Also distinct: environmental/non-medical analytical testing, and biopharmaceutical contract-laboratory services (drug-development work).

The three-tier structure of U.S. lab testing. As of 2024 there were roughly 320,000 CLIA-certified (see Section 7) laboratories of all types: about 9,200 hospital-based labs, roughly 123,000 physician-office labs (each tiny), and about 8,500 independent clinical and anatomic-pathology labs.[3] The independent labs — this NAICS code — are far fewer in number but include the giants that handle the highest volumes and the most complex, centralized testing.

Ownership mix. The segment is barbell-shaped: two very large publicly traded national chains (Quest, Labcorp), a tier of publicly traded specialty/molecular labs, large academic and health-system reference labs (Mayo, ARUP, Cleveland Clinic), and a long tail of privately held regional and niche labs — many now owned or backed by private equity, or being folded into the majors. The federal data do not provide an ownership split.

3. How big it is

Federal statistics for NAICS 621511 (independent medical labs). Years differ by source and should not be combined into a single-period estimate.

Concentration (share of the segment's revenue held by the largest firms): the top 4 firms take 36%, the top 8 take 41.8%, the top 20 take 51.7%, and the top 50 take 62.7%.[4] The Herfindahl-Hirschman Index (HHI), a standard concentration measure, is suppressed in the federal data, so we do not state or estimate it. The read: a meaningful national scale layer at the top, then a long, fragmented tail of regional and specialty operators — neither a pure duopoly nor a purely fragmented market.

The undercount caveat — important here. These figures understate diagnostic testing overall, for two reasons. First, by design: 621511 excludes hospital labs (NAICS 622) and physician-office labs (NAICS 6211), which is where the majority of U.S. testing actually happens. Second, by survey method: County Business Patterns excludes the self-employed, businesses without employees or an employer identification number, and most government employees; the Economic Census is primarily a paid-employee business census and generally excludes government-operated establishments.[29] So the $56 billion is an accurate measure of the employer-based independent-lab economy, not total U.S. lab spending. Industry estimates put total U.S. clinical laboratory testing at roughly $80–90+ billion a year, with hospital-based labs alone accounting for more than half of that testing revenue.[7] When you hear "$80 billion market," that is the whole testing pie; the $56 billion is the independent slice.

4. The investable universe

Unlike many niche industries, this one has real public-market depth — two scale operators plus a genuine cohort of specialty testers. These names are not equally pure plays on 621511. Figures are most recent full-year 2025 unless noted.

National scale operators (the "core" pure-plays):

Labcorp's total includes a large Biopharma Laboratory Services (contract-research) arm — roughly 22% of revenue — which is clinical-trial services, not lab testing under 621511; its Diagnostics segment (~$10.9B) is the comparable business.[8] Quest is essentially a pure diagnostic-testing company.[9]

Specialty / molecular / genomic testers (faster growth, higher risk, several not yet profitable):

Other listed players in the neighborhood include CareDx (NASDAQ: CDNA, transplant testing) and Myriad Genetics (NASDAQ: MYGN, hereditary cancer). OPKO Health (NASDAQ: OPK) offers indirect, shrinking exposure through its BioReference lab business, having sold selected clinical, reproductive, women's-health, and oncology testing assets to Labcorp in 2024–2025.[16] Sonic Healthcare (ASX: SHL; SKHHY ADR) is a large Australia-listed operator with major U.S. operations — including its Sonora Quest joint venture — and is the main international-listed way in.[8]

Major private / non-investable owners:

• PathGroup — physician-led pathology and clinical-lab platform; GTCR became majority owner in a 2022 recapitalization, with Pritzker Private Capital, Vesey Street Capital Partners, management, and physicians retaining minority stakes.[22]
• Genova Diagnostics — privately held specialty lab; majority-owned by Levine Leichtman Capital Partners alongside management.[23]
• Millennium Health — privately held specialty lab focused on medication monitoring and drug testing (ultimate owner not publicly disclosed).
• Mayo Clinic Laboratories and ARUP Laboratories (University of Utah) — non-profit reference labs.[24]
• Cleveland Clinic Laboratories — a health-system reference lab serving outside clients as well as its own patients.[25]
• Sonora Quest — a Quest–Banner Health joint venture. A large field of regional and specialty labs is privately held, much of it private-equity-backed; hospital systems (Ballad Health, Allina, University Hospitals, and others) have been selling their outreach labs to Quest and Labcorp rather than run them.[17]

5. How the money works

A medical lab is a high-fixed-cost, high-volume, price-taking business. Owners make money on the spread between what they're paid per test and the marginal cost of running it — with big instruments, automation lines, courier fleets, and pathologists as largely fixed overhead. A useful shorthand:

Revenue ≈ requisition volume × tests per requisition × realized reimbursement per test.

Quest explicitly identifies requisition volume and revenue per requisition as its primary performance measures.[9]

The core drivers of profit:

• Volume — measured in requisitions (a doctor's test order, which may bundle several tests) or specimens. Volume is the engine; Quest grew requisition volume 12.3% in 2025 (3.4% organic, the rest from acquisitions).[9]
• Revenue per requisition / price mix — a routine cholesterol panel pays a few dollars; an advanced genomic or oncology test can pay hundreds to thousands. Mix shift toward molecular testing lifts revenue per test.
• Cost per test / capacity utilization — automation and scale drive unit cost down. Because so much cost is fixed, running the automation lines fuller is where margin comes from — this is the industry's central operating-leverage story. Independent labs' centralized processing lets them run tests at an estimated 30–40% lower per-test cost than many hospital labs.[7]
• Collections quality — labs bill many payers and face denials, patient bad debt, and slow pay. Getting paid (days sales outstanding, denial rates) is a real profit lever, not a back-office footnote.

Principal costs: technologists, pathologists, and phlebotomists; reagents and consumables; specimen collection and courier routes; instruments, facilities, and laboratory information systems; and billing/compliance/payer-appeal functions.[8] Volume can be seasonal (falling over holidays and vacations) and disrupted by severe weather or public-health events.[9]

Who pays (the payer mix). A lab's revenue comes from Medicare, Medicaid, commercial insurers, patients (self-pay/deductibles), and "client bill" arrangements (a hospital or physician group that orders and pays directly). Crucially, a lab does not set most of its prices. Medicare pays under the CLFS — Clinical Laboratory Fee Schedule, an administered price list.[18] Under PAMA (the Protecting Access to Medicare Act of 2014), Medicare's CLFS rates are pegged to the weighted-median price that private insurers actually pay, refreshed periodically.[18][19] So the whole revenue line is exposed to government fee schedules and payer contracting — the defining economic risk of the business (Section 9).

What good looks like: steady mid-single-digit organic volume growth, expanding margins as automation absorbs volume, disciplined collections, and free cash flow returned to owners. Both majors are strong cash generators — Labcorp produced $1.21B of free cash flow and Quest $1.9B of operating cash flow in 2025.[8][9] The specialty testers run the opposite way: they burn cash to build volume and win insurance coverage for novel tests, betting on scale later.

Note: the ground-truth federal file contains no industry-wide capacity-utilization, average-reimbursement, margin, or input-cost figures; those are not stated here.

6. What drives demand

• Demographics. By 2030 nearly one in five U.S. residents will be 65 or older, and older patients carry more chronic conditions — each generating recurring testing.[20] This is the industry's most durable tailwind.
• Chronic disease burden. Diabetes, cardiovascular disease, and cancer all require ongoing monitoring — repeat tests, not one-offs.[1]
• Shift to early detection and precision medicine. Genomic profiling of tumors, hereditary-risk testing, prenatal screening, and multi-cancer early-detection tests are the fastest-growing, highest-price categories — the reason specialty testers grow 20–40% while routine testing grows low single digits.[11][12]
• Cancer-recurrence monitoring (MRD — minimal residual disease). Blood tests that track whether a treated cancer is coming back (e.g., Natera's Signatera, Guardant's liquid biopsies) are a large, still-early market.[11][12]
• Transplant and reproductive/inherited-disease testing — recurring, specialized volume for the molecular labs.[11]
• Health-system outsourcing. Systems increasingly hand outreach and reference testing to scaled operators. Labcorp reported signing or completing 13 health-system and regional-lab collaborations in 2025.[8]
• Physician-visit and coverage volumes. Testing follows doctor visits and insured lives; utilization softens in recessions or when patients defer care, and spiked massively during COVID-19 — a boom that has since normalized, distorting year-over-year comparisons.

Routine testing is defensive — people get sick regardless of the economy — but it is not perfectly recession-proof: it tracks physician visits, elective procedures, and employment-linked insurance coverage.

7. Regulation

This is a heavily regulated industry; regulation is both a moat (barriers to entry) and a risk.

• CLIA — Clinical Laboratory Improvement Amendments of 1988. Any U.S. lab testing human specimens for health purposes must hold a CLIA certificate — a facility generally needs one if it performs even a single test on human-derived material for diagnosis, prevention, treatment, or health assessment (research testing is excluded). CMS (the Centers for Medicare & Medicaid Services) administers CLIA with the CDC and FDA, and tests are graded by complexity (waived, moderate, high). This is the license to operate.[26]
• Reimbursement rules — CMS / CLFS / PAMA. Medicare sets lab prices administratively via the CLFS, tied under PAMA to private-payer medians; coverage and "medical necessity" determinations also gate what gets paid.[18][19]
• FDA and Laboratory-Developed Tests (LDTs) — a major recent swing. Many specialty tests are "laboratory-developed tests," designed and run in-house by a single lab. In 2024 the FDA finalized a rule to regulate LDTs as medical devices — a costly compliance burden for specialty labs. A federal court vacated the rule on March 31, 2025 (in ACLA and AMP v. FDA), and on September 19, 2025 the FDA formally reverted the regulation to its prior text, restoring the long-standing enforcement-discretion status quo.[21] This removed a significant overhang for the specialty/genomic testers — though Congress or a future rulemaking could still impose a framework.
• Fraud-and-abuse and privacy laws: the Anti-Kickback Statute (bars remuneration to induce federally reimbursable referrals), the Stark physician self-referral law (which specifically names clinical-lab services), the False Claims Act and related billing rules,[27] HIPAA (Health Insurance Portability and Accountability Act) protecting patient data and cybersecurity, and the No Surprises Act, which can affect out-of-network lab billing tied to in-network care.[28]
• State licensure — New York and California impose stricter regimes on top of federal CLIA.

8. Competitive dynamics and consolidation

Scale wins the routine business. National logistics (couriers, patient service centers, in-office phlebotomists), automation, broad payer contracts, large test menus, and electronic ordering/result connectivity favor the largest operators. Yet even the giants are not monopolists: within total U.S. lab testing (~$80B+), Quest and Labcorp each hold only roughly 10–15% by revenue, and the top handful combined sit around 35% — because hospitals still run the majority of testing in-house.[7][17] Within the independent-lab segment specifically, the two majors clearly dominate (consistent with the top-4 holding 36% of NAICS 621511 receipts).[4] Regional and physician-led labs still compete on faster turnaround, pathologist access, local hospital relationships, and service quality.

Consolidation is the defining trend:

• Hospital outreach labs are being sold to the majors. Health systems (Ballad, Allina, University Hospitals, and others) increasingly sell their outpatient/outreach lab businesses to Quest or Labcorp — pulling volume that used to sit with many small local labs into two national platforms. Both majors made numerous such transactions in 2024–2025.[8][17]
• Private-equity roll-ups are consolidating regional and specialty labs and physician-led pathology groups — e.g., GTCR's recapitalization of PathGroup.[22]
• The majors buy capabilities, not just volume — acquiring molecular, oncology, women's-health, and neurology testing (Labcorp's purchases of selected OPKO/BioReference assets among them) to move up the value curve as routine testing commoditizes.[16]

Specialty labs compete on menu and evidence, not scale. Their moat is clinical validation, guideline inclusion, and insurance coverage for a specific test — which is why so much of their spending goes to studies and payer negotiations rather than instruments.

9. Risks

• Reimbursement / pricing power. The single biggest risk: labs don't set prices. PAMA-driven Medicare cuts have repeatedly threatened the CLFS. They have been softened — CY2025 saw a 0% reduction, and the Consolidated Appropriations Act of 2026 again delayed the phase-in (no cut in 2026, future annual cuts capped at 15% for 2027–2029) — but the structural downward pressure on routine-test prices has not gone away.[18] Commercial payers push the same direction.
• Coverage lag for new tests. A novel genomic test can be clinically valuable yet unpaid for years until payers grant coverage — the core risk for the specialty cohort, several of which are still unprofitable.[12]
• Denials and patient bad debt. Rising deductibles push more cost onto patients, who pay slowly or not at all.
• Commoditization of routine testing. High-volume, low-price tests are a race to the lowest cost — punishing subscale labs.
• Labor. Shortages of pathologists, medical technologists, and phlebotomists raise costs and cap capacity.
• Compliance / billing litigation. Complex multi-payer billing creates exposure to False Claims Act, anti-kickback, and unnecessary-testing enforcement — up to exclusion from government programs.
• Quality failures. CLIA lapses, inaccurate results, specimen mishandling, or delayed turnaround carry clinical and legal consequences.
• Cybersecurity. Labs hold large volumes of protected health information — a standing breach target.
• Technology / channel disruption. Point-of-care, at-home, and direct-to-consumer testing could pull volume out of central labs; hospitals may also retain testing internally rather than outsource.
• Regulatory reversal. The LDT rule is gone for now, but a future FDA action or an act of Congress could re-impose device-style oversight on specialty tests.[21]
• Deal and revenue-durability risk. M&A integration failures, excessive leverage, or overpayment for acquired labs; and episodic pandemic/screening surges that do not recur.

Private investors face an added information risk: private labs disclose far less than public companies, and the federal data omit portions of government, hospital, and very-small-operator activity.

10. How to invest and the outlook

Public-market routes:

• Steady cash generators: Quest (DGX) and Labcorp (LH) — the two national pure-plays, with GDP-plus volume growth, real margins, dividends and buybacks, and the role of acquirers in consolidation. Labcorp's ~22% biopharma/CRO segment gives it a different (drug-development-linked) exposure alongside pure testing, so it should not be valued as if all revenue were 621511.[8][9]
• Growth / specialty exposure: the molecular and genomic testers (Exact Sciences, Natera, Guardant Health, NeoGenomics, Veracyte, Fulgent, plus CareDx and Myriad) — 20–40% growth in the best cases, but higher valuation risk and, for several, no profits yet.[10][11][12][13][14][15]
• International / indirect: Sonic Healthcare (ASX: SHL) for a large operator with U.S. and global scale; OPKO (OPK) for shrinking, indirect BioReference exposure.[16]
• Picks-and-shovels (adjacent codes): the tools and in-vitro-diagnostic (IVD) suppliers upstream of the labs are a different NAICS but a related bet.

Public-company analysis should center on organic test volume, revenue per requisition, reimbursement trends, specialty-test mix, operating margins, free cash flow, capital spending, leverage, and valuation multiples relative to business purity.

Private-market routes: private-equity-backed regional lab platforms; physician-led pathology groups; buying or partnering on hospital outreach labs; laboratory-management contracts; venture investment in diagnostic startups chasing coverage for a new test; and lab software/automation providers. Diligence should emphasize CLIA and state licenses, payer contracts, billing history, test coverage, pathologist retention, quality metrics, specimen logistics, instrument utilization, customer concentration, normalized earnings, capital needs, and integration risk. The marquee academic reference labs (Mayo, ARUP, Cleveland Clinic) are non-profit or health-system-owned and off-limits to investors.

Near-term outlook (forward-looking judgment). The base case is durable: demographics and chronic disease keep volumes growing, and precision-medicine testing keeps mixing revenue upward. Consolidation should continue as hospitals shed labs and the majors and PE keep buying. The recent PAMA delays and the death of the FDA's LDT rule have removed two overhangs and are net positives — especially for specialty testers — while automation and AI keep pushing costs down. The persistent counterweight is pricing: routine-test reimbursement grinds lower over time, so the durable winners are those with either genuine scale (lowest cost per test) or a differentiated, well-reimbursed test menu. The weakest investments will be those leaning on temporary testing surges, uncertain reimbursement, weak billing controls, or unproven laboratory-developed tests. It is a defensive, consolidating, demographically favored industry whose ceiling is set less by demand than by what payers will pay.

---

Sources

1. National Health Council / American Clinical Laboratory Association, "Clinical Laboratory Testing Is Essential to Patient-Centered Healthcare" (the ~70%-of-medical-decisions figure and chronic-disease demand), 2023–2024. https://nationalhealthcouncil.org/blog/guest-blog-clinical-laboratory-testing-is-essential-to-patient-centered-healthcare/; https://www.acla.com/the-power-of-knowing/
2. U.S. Census Bureau / NAICS, "NAICS Code 621511 — Medical Laboratories" (definition, inclusions, and excluded adjacent codes 621512, 621991, 339113/115/116), 2022. https://www.census.gov/naics/?details=621511&input=621511&year=2022
3. MarkNtel Advisors / Umbrex, "How the Medical Labs & Diagnostics Industry Works" (≈320,000 CLIA labs: ~9,200 hospital, ~123,000 physician-office, ~8,500 independent), 2024. https://umbrex.com/resources/how-industries-work/healthcare-and-life-sciences/how-the-medical-labs-diagnostics-industry-works/
4. U.S. Census Bureau, 2022 Economic Census — Concentration ratios, NAICS 621511 (receipts $56.1B; 4,527 firms; CR4 36%, CR8 41.8%, CR20 51.7%, CR50 62.7%; HHI suppressed).
5. U.S. Census Bureau, County Business Patterns, NAICS 621511 (16,635 establishments; 232,333 employees; $17.2B annual payroll; $4.57B first-quarter payroll), 2023.
6. U.S. Small Business Administration, Table of Small Business Size Standards, NAICS 621511 ($41.5M receipts), 2023.
7. Grand View Research / Mordor Intelligence / Fortune Business Insights, "Clinical Laboratory Services Market" (total U.S. lab testing ~$80B+; hospital labs >50% of testing revenue; independent labs' 30–40% cost advantage), 2025. https://www.grandviewresearch.com/industry-analysis/clinical-laboratory-services-market; https://www.mordorintelligence.com/industry-reports/clinical-laboratory-services-market
8. Labcorp Holdings Inc., "2025 Fourth Quarter and Full Year Results" and 2025 Form 10-K (FY2025 revenue $13.95B; Diagnostics ~$10.9B / ~78%; biopharma ~22%; FCF $1.21B; ~71,000 employees; 2,200+ patient service centers; 13 health-system/regional-lab collaborations in 2025), Feb 2026. https://www.prnewswire.com/news-releases/labcorp-announces-2025-fourth-quarter-and-full-year-results-302689090.html; https://www.sec.gov/Archives/edgar/data/920148/000092014826000111/lh-20251231.htm
9. Quest Diagnostics Inc., "Fourth Quarter and Full Year 2025 Financial Results" and 2025 Form 10-K (FY2025 revenue $11.0B; ~244M requisitions; requisitions +12.3% / +3.4% organic; net income $992M; operating cash flow $1.9B; requisition volume and revenue per requisition as core metrics), Feb 2026. https://www.prnewswire.com/news-releases/quest-diagnostics-reports-fourth-quarter-and-full-year-2025-financial-results--provides-guidance-for-full-year-2026-increases-quarterly-dividend-7-5-to-0-86-per-share-302683210.html; https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm
10. Exact Sciences Corp., "Record Fourth Quarter and Full Year 2025 Results" (FY2025 revenue $3.25B; screening $2.53B; precision oncology $717M), Feb 2026. https://www.nasdaq.com/press-release/exact-sciences-announces-record-fourth-quarter-and-full-year-2025-results-2026-02-13
11. Natera Inc., "Fourth Quarter and Full Year 2025 Financial Results" (FY2025 revenue $2.31B, +35.9%; cell-free DNA testing in women's health, oncology, organ health), Feb 2026. https://investor.natera.com/news/news-details/2026/Natera-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx
12. Guardant Health Inc., "Fourth Quarter and Full Year 2025 Financial Results" (FY2025 revenue ~$981M, +33%; blood- and tissue-based oncology testing), Feb 2026. https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Outlook/default.aspx
13. NeoGenomics Inc., FY2025 results / 2025 annual report (FY2025 revenue $727M, +10%; oncology pathology and molecular testing), 2025–2026. https://stockanalysis.com/stocks/neo/revenue/; https://www.sec.gov/Archives/edgar/data/1077183/000107718326000015/a2026ars.htm
14. Fulgent Genetics Inc., FY2025 revenue (~$323M; precision diagnostics, anatomic pathology, therapeutic-development activity), 2025–2026. https://stockanalysis.com/stocks/flgt/revenue/; https://www.sec.gov/Archives/edgar/data/1674930/000119312526079169/flgt-20251231.htm
15. Veracyte Inc., 2025 Form 10-K (specialty genomic diagnostics run through its laboratory network), 2026. https://www.sec.gov/Archives/edgar/data/1384101/000138410126000010/vcyt-20251231.htm
16. OPKO Health Inc. / BioReference, 2025 Form 10-K and company disclosures (indirect BioReference lab exposure; sale of selected clinical, reproductive, women's-health, and oncology testing assets to Labcorp in 2024–2025), 2026. https://www.opko.com/investors/sec-filings/all-sec-filings/content/0001193125-26-076596/opk-20251231.htm
17. Becker's Hospital Review / Laboratory Economics, "Health systems selling lab assets" (Ballad, Allina, University Hospitals outreach-lab sales to Labcorp/Quest; combined ~35% top-player share of total testing), 2024–2025. https://www.beckershospitalreview.com/hospital-transactions-and-valuation/7-health-systems-selling-lab-assets/
18. Centers for Medicare & Medicaid Services, "Clinical Laboratory Fee Schedule: 2025 Annual Update" and CLFS/PAMA reporting resources (CY2025 0% reduction; CAA 2026 delay; 15%/yr caps 2027–2029; next reporting May–Jul 2026), 2025–2026. https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule/clfs-pama-reporting-resources
19. National Independent Laboratory Association, "PAMA" (Medicare CLFS rates tied to weighted-median private-payer rates), 2025. https://www.nila-usa.org/nila/PAMA.asp
20. American Society for Clinical Laboratory Science, "Role of the Clinical Laboratory in Response to an Expanding Geriatric Population" (nearly 1 in 5 U.S. residents aged 65+ by 2030), 2020s. https://ascls.org/expanding-geriatric-population/
21. Sidley Austin LLP / American Hospital Association, "FDA's Laboratory-Developed Tests (LDT) Rule Struck Down" and "FDA vacates final rule regulating lab-developed tests" (federal court vacated the LDT rule March 31, 2025; FDA reverted the rule Sept 19, 2025). https://www.sidley.com/en/insights/newsupdates/2025/04/fdas-laboratory-developed-tests-ldt-rule-struck-down-in-major-test-of-loper-bright; https://www.aha.org/news/headline/2025-09-18-fda-vacates-final-rule-regulating-lab-developed-tests-medical-devices
22. GTCR / PathGroup, "GTCR Announces Recapitalization of PathGroup" (GTCR majority owner 2022; Pritzker Private Capital, Vesey Street Capital Partners, management, physicians minority), 2022. https://pathgroup.com/wp-content/uploads/PathGroup_GTCR-Announces-Recapitalization-of-PathGroup_Press-Release_FINAL_05.2022.pdf
23. Genova Diagnostics, ownership disclosure (Levine Leichtman Capital Partners majority owner alongside management). https://www.prnewswire.com/news-releases/genova-diagnostics-announces-new-ceo-300103441.html
24. Mayo Clinic, "Mayo Medical Laboratories Rebrands as Mayo Clinic Laboratories" (nonprofit health-system reference lab), 2018. https://newsnetwork.mayoclinic.org/discussion/mayo-medical-laboratories-rebrands-its-name-as-mayo-clinic-laboratories/
25. Cleveland Clinic, "Pathology and Laboratory Medicine Departments" (health-system reference lab serving external clients), 2026. https://my.clevelandclinic.org/departments/pathology/depts
26. Centers for Medicare & Medicaid Services, "Clinical Laboratory Improvement Amendments (CLIA)" (CMS-administered; certification required for testing human-derived material; research testing excluded), 2026. https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments
27. U.S. Department of Health and Human Services Office of Inspector General / CMS, "Fraud and Abuse Laws" and "Physician Self-Referral" (Anti-Kickback Statute, Stark law covering clinical-lab services, False Claims Act), 2026. https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/; https://www.cms.gov/medicare/regulations-guidance/physician-self-referral
28. U.S. Department of Health and Human Services / CMS, "HIPAA Security Rule" and "No Surprises Act Overview" (protected health information/cybersecurity; out-of-network billing protections), 2026. https://www.hhs.gov/hipaa/for-professionals/security/index.html; https://www.cms.gov/files/document/nsa-keyprotections.pdf
29. U.S. Census Bureau, "County Business Patterns Methodology" and "Economic Census Overview" (CBP excludes self-employed, non-EIN, and most government employees; Economic Census is primarily a paid-employee business census), 2026. https://www.census.gov/programs-surveys/cbp/technical-documentation/methodology.html; https://www.census.gov/econ/overview/mu0000.html